From: Clinical and lung function outcomes in a cohort of children with severe asthma
Severe Asthma Clinic children (n = 23) | |
---|---|
Hospital Admissions in the previous year | 10 (43)c |
Number of Hospital admissions in the previous year | 3/3(0.9/1–4)d |
Number of children with Positive Skin Prick Test | 19 (83)c |
Number of children with serum Specific IgE positive | 18 (78)c |
● Aspergillus | 4 (22) c |
● D pteronys | 15 (65) c |
● Australia treemix | 4 (22) c |
● Cat epithelia | 7 (30) c |
● Dog dander | 9 (50) c |
● Weed mix | 4 (22) c |
● Grass mix | 7 (30) c |
● Mould mix | 4 (22) c |
Blood eosinophils levelsa | 909/800 (66/0–2900) d |
Serum Immunoglobulin E (IU/mL) a | 1257/1210 (1125/165–4565)d |
Age at symptoms onset in yearsa | 3.7/1.5 (3.9/0.5–12) d |
Age at visit date in years | 11.4/12 (2.7/4–16) d |
ICSb (mcg/day) | 1851/2000 (642/640–4000) d |
Number of children with ACT score ≤ 19 | 17 (74) c |
ACT score | 14.2/12 (5.4/8–25) d |
Quality of Life Questionnaire score a | 5.2/5.3 (1.1/3.1–7) d |
ACQ-5a | 1.8/1.8 (1/0–3.8)d |
PI-ED | 9(38)c |
● Anxiety ● Depression | 5/3 (6.6/0–20) 0.6/0 (1.3/0–3) |
Number of children under treatment with Azithromycin | 7 (30) c |
Nasal steroids | 16 (70)c |
Bronchoscopy | 9 (39c) |
Bronchoalveolar Lavage Fluid (BALF)a | 7 (30) c |
● % Macrophage | 86.4/88 (12.6/68–99.5) d |
● % Eosinophil | 2.8/1.3 (7.5/0.5–21) d |
● % Lymphocyte | 7.9/7.5 (8.8/0.5–26) d |
● % Neutrophil | 4.7/1 (8.0/0.5–19) d |